Equillium develops Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells in severe autoimmune and inflammatory disorders. The company also utilizes a proprietary multi-cytokine inhibitor platform to address the unmet medical needs associated with various inflammatory conditions.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.

MatriSys Bio is developing a novel class of biopharmaceuticals that utilize beneficial bacteria derived from healthy human skin to treat chronic inflammatory skin conditions. This approach aims to restore skin homeostasis for millions of patients suffering from dermatological diseases such as atopic dermatitis and acne, reducing reliance on steroids and antibiotics.

NeuraLace offers Axon Therapy®, a 100% non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed to treat chronic neuropathic pain without the need for needles or surgical interventions. This technology provides significant pain reduction, minimizing reliance on opioids and improving patient quality of life through targeted neuromodulation.

Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for hematological malignancies and prostate cancer by exploring untapped biological pathways involved in cancer progression. The company addresses the critical unmet medical needs of patients with these cancers through its diverse pipeline of treatment modalities.

Persephone Biosciences utilizes artificial intelligence and synthetic biology to develop microbial-based immunotherapies that restore human microbiomes, addressing the health impacts of damaged ecosystems. Their approach aims to enhance therapeutic responses and improve patient outcomes in the fight against cancer.

This company provides a Proof-as-a-Service model for generating large-scale, diverse clinical trial data for wellness products. They utilize adaptive trial formats and integrated biomarkers to deliver precision health insights rapidly. This evidence supports stronger product claims, optimized formulations, and improved consumer targeting.